NCT02389348View on ClinicalTrials.gov

A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Malaria
Interventions
DRUG

DSM265

Single oral doses of DSM265

DRUG

OZ439

Single oral doses of OZ439

Trial Locations (1)

4006

Q-Pharm Clinics, Herston

Sponsors
All Listed Sponsors
collaborator

Q-Pharm Pty Limited

INDUSTRY

collaborator

QIMR Berghofer Medical Research Institute

OTHER

collaborator

Clinical Network Services (CNS) Pty Ltd

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT02389348 - A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265 | Biotech Hunter | Biotech Hunter